Terry J. Rosen - 27 Feb 2025 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Role: Chief Executive Officer, Director
Signature: /s/ Carolyn Tang, Attorney-in-Fact
Issuer symbol: RCUS
Transactions as of: 27 Feb 2025
Net transactions value: +$201,465
Form type: 4
Filing time: 27 Feb 2025, 19:05:56 UTC
Previous filing: 27 Jan 2025
Next filing: 26 Jun 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RCUS	Common Stock	Purchase	$201,465	+19,800	+0.78%	$10.18	2,554,160	27 Feb 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.13 to $10.185, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.13 to $10.185, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.